Apyx Medical Reports Strong 2025 Revenue Growth and Significantly Reduced Losses, Driven by New Product Launches

summarizeSummary

Apyx Medical reported strong 2025 revenue growth and significantly narrowed its net losses, driven by new product launches and cost-saving measures, while securing additional capital for future operations.

check_boxKey Events

• Strong Revenue Growth and Reduced Losses

  Total revenue increased by 9.9% to $52.8 million in 2025, with the Surgical Aesthetics segment growing 17.4% to $45.3 million. The company significantly reduced its loss from operations to $6.4 million (from $18.8 million in 2024) and net loss attributable to stockholders to $11.2 million (from $23.5 million in 2024).

• Improved Operational Cash Flow

  Net cash used in operating activities improved substantially from $18.0 million in 2024 to $8.0 million in 2025, reflecting the positive impact of cost-saving restructuring and increased sales.

• Strategic Product Launches and Market Expansion

  The company commercially launched its AYON Body Contouring System in September 2025 following FDA clearance in May 2025, and expanded Renuvion's market presence with a launch in China in July 2025.

• Capital Raise and Future Financing Flexibility

  Apyx Medical completed a $9.1 million public offering in November 2025 and filed a new $100 million shelf registration statement in December 2025, providing capital for working capital and general corporate purposes, and flexibility for future financing.

auto_awesomeAnalysis

Apyx Medical's 2025 annual report highlights a notable improvement in financial performance, with a 9.9% increase in total revenue and a substantial reduction in operating and net losses. The Surgical Aesthetics segment, a key growth driver, saw a 17.4% revenue increase, fueled by the commercial launch of the AYON Body Contouring System and Renuvion in China. While the company continues to incur net losses and cash outflows from operations, the significant reduction in cash burn and successful capital raises (including a $9.1 million offering and a new $100 million shelf registration) provide crucial liquidity and extend its operational runway. Investors should monitor the continued commercialization success of AYON and Renuvion, as well as the management of ongoing product liability litigation, which the company believes is adequately covered by insurance. The full audited results confirm the preliminary figures released earlier today, providing comprehensive detail on the company's strategic progress and financial health.